Skip to content
Review

Crosstalk and Convergence in Alzheimer's Disease: Integrating Brain Injury, Neuroinflammation, and Precision Medicine for Next-Generation Therapeutics.

Sep 2026 · Current Neuropharmacology · 0 citations
Medicine

TL;DR

This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction, and individual vulnerability.

Abstract

Alzheimer's Disease (AD) is a complex disorder whose underlying biology is not fully explained by traditional single-pathway models. For several decades, research has largely focused on the roles of amyloid-β and tau in the formation and deposition of plaques and neurofibrillary tangles associated with AD pathology and neurodegeneration. Despite this sustained focus, therapeutic strategies targeting amyloid-β and tau alone have shown limited success in altering the natural course of the disease. Accordingly, there is a clear need for an adaptive and integrative framework that better captures the heterogeneity and dynamic nature of disease progression over time. This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction (impaired supply chain), synaptic dysfunction, and individual vulnerability. Evidence is presented to illustrate (1) how the traumatic and chronic nature of brain injury predisposes the brain to persistent inflammation and neurodegeneration; (2) how astrocytic and microglial activation states contribute to synaptic dysfunction and neuronal damage; and (3) how pathological interactions among amyloid pathology, tau dysregulation, and immune signaling collectively exacerbate neuroinflammatory responses and accelerate disease progression in AD.

View source

Similar papers

Review Aug 2026

Neuroinflammatory and molecular pathways in Alzheimer’s disease: mechanistic crosstalk and emerging therapeutic opportunities

Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.

Abhay Thakur, Rohit Sharma, Sneha Kumari et al. · 0 citations
Review Open access Aug 2026

Microglia-mediated neuroinflammation in Alzheimer’s disease: mechanisms and emerging therapeutic targets

A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...

Lian-Jing Xu, Ying Zhang, Li Jiang et al. · 0 citations
Review Open access Sep 2026

The Role of Neuroinflammation in Alzheimer's Disease: Molecular Mechanisms and Emerging Therapeutic Approaches

This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...

Shreyansh Goswami · 0 citations
Review Open access Sep 2026

Translating Molecular Pathogenesis into Therapeutics: Emerging Strategies and Clinical Prospects for Alzheimer’s Disease

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...

Mona Piplani, Shivani Thakur, Pankaj Kumar et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...

P. Chmielewski · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.